Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab with or without laser versus laser for diabetic macular edema
NL-OMON32224Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Oct 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in diabetic macular edema (DME) (3 arms), sponsored by Novartis. Planned start Oct 2008; status: not yet recruiting.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NL-OMON32224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32224.